Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters

Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters

The metabolic syndrome in HIV infected patients is particularly associated with the use protease inhibitors. Atazanavir is an inhibitor of the cytochrome P 450 (CYP) system, in particular CYP3A4 and CYP2C9 which can affect the metabolism of several drugs. To treat metabolic syndrome in HIV patients...

Full description

Bibliographic Details
Main Authors: Thirumal Eswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad
Format: Article
Language:English
Published: International Association of Physical Chemists (IAPC) 2016-10-01
Series:ADMET and DMPK
Subjects:
AIDS
Drug drug interaction
hypoglycaemic activity
Liver dysfunction
Peak plasma concentration Cmax
Area under the curve Auc
Clearance
Elimination half life.
Online Access:http://pub.iapchem.org/ojs/index.php/admet/article/view/328

Internet

http://pub.iapchem.org/ojs/index.php/admet/article/view/328

Similar Items